Blood Typing Market (By Product & Services: Instruments, Reagents & Consumables; By Test Type: Antibody Screening, HLA Typing; By Technique; By Application; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Blood Typing Market Size and Trends

The global blood typing market size was estimated at USD 1.98 billion in 2023 and it is expected to surpass around USD 5.29 billion by 2033, poised to grow at a CAGR of 10.33% from 2024 to 2033.

Key Pointers

• North America led the global market with the largest market share of 45% in 2023.
• Asia Pacific is predicted to grow at the remarkable CAGR over the forecast period.
• By Product & Services, the reagents and consumables segment generated the maximum market share of 72% in 2023.
• By Product & Services, the services segment is expected to expand at the highest CAGR from 2024 to 2033.
• By Test Type, the antibody screening segment generated the maximum market share of 39% in 2023.
• By Technique, the PCR-based and microarray-based segment contributed the largest market share of 53% in 2023.
• By Application, the diagnostic testing segment had the largest market share of 55% in 2023.
• By End-use, the diagnostic laboratories segment contributed more than 44% of revenue share in 2023.

Blood Typing Market Overview

The blood typing market is witnessing significant growth owing to advancements in healthcare infrastructure and rising demand for blood transfusions in various medical procedures. Blood typing, also known as blood group typing, refers to the process of determining the blood group and Rh factor of an individual's blood. This information is crucial for blood transfusions, organ transplants, and prenatal care.

Blood Typing Market Growth Factors

The growth of the blood typing market is driven by an advancement in healthcare infrastructure and technology are enhancing the accuracy and efficiency of blood typing procedures, thereby driving market expansion. Secondly, the increasing prevalence of chronic diseases and trauma cases necessitates a higher demand for blood transfusions, stimulating market growth. Additionally, growing awareness about the significance of blood donation and blood typing in medical procedures is further fueling market demand.

U.S. Blood Typing Market Size 2024 to 2024

The U.S. blood typing market size was estimated at around USD 0.62 billion in 2023 and it is projected to hit around USD 1.66 billion by 2033, growing at a CAGR of 10.34% from 2024 to 2033.

North America dominated the blood typing market with a revenue share of 45% in 2023, owing to factors such as the region's well-developed healthcare infrastructure and a large number of transfusions happening in the region. Major companies operating in the blood group typing sector, such as Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, and Thermo Fisher Scientific Inc., have significant expertise, resources, and established distribution networks. The companies' comprehensive product portfolios, expansive global footprint, and well-established brand recognition further support region dominance.

The blood typing market in Asia Pacific is anticipated to witness at the fastest CAGR over the forecast period. The increasing number of donation activities and the rising incidence of trauma, accidents, and surgeries requiring transfusion are key drivers. In addition, the growing demand for blood group typing in prenatal and postnatal testing, along with the stringency of prudent transfusions, is expected to boost the market growth.

Blood Typing Market Trends:

• Rising Demand for Blood Transfusions: The increasing prevalence of chronic diseases, rising number of trauma cases, and growing surgical procedures necessitate a higher demand for blood transfusions, driving the growth of the blood typing market.
• Growing Awareness and Importance of Blood Typing: There is a rising awareness among healthcare professionals and the general population about the significance of blood typing in medical procedures, including blood transfusions, organ transplants, and prenatal care.
• Shift towards Point-of-Care Testing: There is a notable trend towards point-of-care blood typing testing, which allows for quicker results and facilitates immediate decision-making in emergency situations, thereby driving market growth.
• Expansion in Emerging Markets: Emerging economies in regions like Asia-Pacific and Latin America are witnessing rapid growth in the blood typing market due to increasing healthcare investments, rising disposable income, and growing awareness about blood-related disorders.
• Focus on Personalized Medicine: The trend towards personalized medicine is influencing the blood typing market, with a growing emphasis on matching blood products more precisely to individual patient needs, thereby driving demand for advanced blood typing technologies.

Blood Typing Market Restraints:

• High Costs Associated with Advanced Technologies: The adoption of advanced blood typing technologies often entails significant upfront costs for healthcare facilities, limiting their accessibility, particularly in resource-constrained settings.
• Limited Availability of Skilled Professionals: The complexity of some advanced blood typing techniques requires specialized training and expertise, leading to a shortage of skilled professionals capable of performing these procedures, thereby hindering market growth.
• Concerns Regarding Blood Safety and Compatibility: Despite advancements in blood typing technologies, concerns persist regarding the safety and compatibility of blood products, particularly in cases of rare blood types or alloimmunization, leading to hesitancy among healthcare providers and patients.
• Risk of Transfusion Reactions and Complications: Despite meticulous blood typing procedures, there is always a risk of transfusion reactions and complications, such as hemolytic reactions or transmission of infectious diseases, which can erode patient confidence and affect market demand.

Product & Services Insights

The reagents and consumables segment led the market with the largest revenue share of 72% in 2023 and is anticipated to grow at a lucrative CAGR over the forecast period. The recurring cost associated with frequent requirement of reagents & kits is a significant factor contributing to the market's growth. This constant need for consumables is driven by the high frequency of blood typing tests in various clinical settings, including hospitals, clinical laboratories, and blood banks. Technological advancements continuously drive the development of new and improved reagents, enhancing the accuracy and efficiency of blood typing processes.

The services segment is anticipated to grow at a significant CAGR over the forecast period. The increasing demand for transfusions and organ transplantations, rise in surgical operations, and growing use of reagents and serological fluids in laboratories. The elevated donation rates, which result in more blood sample analysis, also contribute to the expansion of the services segment. The importance of blood group analysis is projected to rise as the trend of donation out of societal concern increases, further driving the demand for services related to blood group testing.

Test Type Insights

Based on test type, the antibody screening segment led the market with the largest revenue share of 39% in 2023, due to the growing volume of prenatal testing, increasing transfusions, and rising prevalence of chronic diseases. Pregnant patients require various screening tests, including blood group and antibody screening, increasing the segment growth. According to a study published in the Journal of Personalized Medicine in April 2023, between 2012 and 2022, there were 51,803 new genetic tests introduced to the market in the U.S., with a significant portion of these being diagnostic tests, which are fundamental for prenatal screening. This indicates a substantial volume of prenatal testing, including blood group and antibody screening, contributing to market growth.

The HLA typing segment is anticipated to grow at the fastest CAGR over the forecast period. The number of individuals on the national transplant waiting list, which stands at 103,223 significantly contributes to this growth. Transplants require HLA typing to ensure compatibility between donor and recipient, crucial for preventing graft rejection and ensuring transplant success. HLA typing allows for more precise matching between donors and transplant patients, reducing the incidence and severity of graft-versus-host disease (GvHD) and increasing long-term survival.

Technique Insights

Based on technique, the PCR-based and microarray-based segment led the market with the largest revenue share of 53% in 2023. The adoption of automated blood typing technologies, including PCR-based and microarray techniques, has improved the speed, standardization, and safety of transfusion diagnostics. A team from Tokyo University of Science has developed a technologically advanced lab-on-a-chip device that can determine a person’s blood type within five minutes, significantly speeding up the process of transfusion in emergency situations. These technologies offer advantages over manual typing, including cost efficiency, increased efficiency, and reduced errors highlighting the market's shift towards automated and high-throughput solutions.

The assay-based techniques segment is expected to grow at a significant CAGR during the forecast period. These techniques, including slide methods, test-tube methods, microplate methods, and gel/column centrifugation, are commonly used in hospitals and blood banks for general blood typing due to their convenience. As technologies continue to evolve, the efficiency and accuracy of these methods contribute significantly to the safety and success of transfusions and transplantation procedures. Increasing requirement for blood during surgical treatments and a growing number of hospitals further fuel the demand for accurate and swift blood group testing procedures, highlighting the essential role of assay-based techniques in the market.

Application Insights

Based on application, the diagnostic testing segment led the market with the largest revenue share of 55% in 2023. The adoption of automated blood analysis technologies, such as PCR-based and microarray techniques, which improves diagnostic speed, standardization, and safety. These technologies offer cost, efficiency, and error reduction benefits, making them attractive for healthcare institutions. The development of lab-on-a-chip devices for rapid blood type determination further enhances diagnostic testing's appeal. This growth is supported by the need for various screening tests during pregnancy, including blood group and antibody screening.

The organ transplants segment is anticipated to grow at the fastest CAGR over the forecast period. Technological advancements, such as the introduction of molecular diagnostics methods such as NGS and PCR, have made organ transplantation more feasible and safer, thereby increasing the market's growth. In addition, the rising incidence of infectious diseases and the aging population contribute to the need for organ transplants, further driving the demand for blood group testing services. The industry growth is also supported by strategic collaborations among firms, which accelerate product innovation and market expansion.

End-use Insights

Based on end-use, the diagnostic laboratories segment led the market with the largest revenue share of 44% in 2023. The rising prevalence of chronic diseases and traumatic injuries, necessitates increased transfusions and organ transplantations. This demand is fueled by the development of advanced blood typing technologies, enhancing accuracy, speed, and efficiency. In addition, growing awareness of the importance of blood typing for safe transfusions and transplantations, coupled with investments in healthcare infrastructure, particularly in emerging economies, drives the demand for blood typing products and services. Government policies and initiatives aimed at improving healthcare access and infrastructure further contribute to market growth.

The blood banks segment is anticipated to grow at the fastest CAGR during the forecast period, driven by several key factors and drivers. The primary reason for this growth is the increasing demand for transfusions and organ transplantations, which necessitate blood typing to ensure compatibility between donors and recipients. This demand is fueled by a combination of factors including the rise in major surgical procedures, the volume of donations, and the growing prevalence of chronic diseases and blood disorders. Furthermore, the establishment of large blood banks and donation campaigns to ensure a constant supply of blood contributes to the market's growth. These initiatives are crucial in meeting the high demand for transfusions and organ transplantations, which in turn drives the need for blood typing services.

Blood Typing Market Key Companies

• Mesa Laboratories, Inc. (Agena Bioscience, Inc.)
• Danaher Corporation (Beckman Coulter)
• Bio-Rad Laboratories, Inc.
• DIAGAST
• Grifols, S.A.
• AXO Science
• Merck KGaA
• Quotient, Ltd.
• Thermo Fisher Scientific
• Immucor, Inc.
• BAG Diagnostics GmbH
• Seegene Inc.

Recent Developments

• In June 2023, Alba by Quotient expanded its operations into the Netherlands and Sweden, marking its entry into new European markets while augmenting its presence in existing ones. Alba offers high-quality blood bank reagents, accompanied by expert support and reliable service. Leveraging Quotient's extensive experience of over 30 years, Alba also provides the MosaiQ solution for advanced diagnostics.
• In May 2023, Bio-Rad introduced the IH-500 NEXT, a fully automated system designed for ID-Cards, aimed at enhancing efficiency within immunohematology laboratories through optimized result interpretation and bolstered cybersecurity measures. The system offers flexibility by accommodating both Bio-Rad and third-party reagents, catering to diverse laboratory preferences and requirements.
• In March 2023, Werfen successfully concluded the acquisition of Immucor, Inc. for approximately USD 2 billion, thereby expanding its portfolio within the specialized diagnostics segment, particularly in the Transfusion and Transplant markets. This strategic move reinforces Werfen's position in these critical healthcare sectors, positioning the company for further growth and innovation.

Blood Typing Market Segmentation:

By Product & Services

• Instruments
• Reagents & Consumables
  • RBC Reagents
  • Antisera Reagents
  • Anti-Human Globulin Reagents
  • Blood Saline Reagents
• Services

By Test Type

• Antibody Screening
• HLA Typing
• Cross-matching
• ABO Blood Tests
• Others

By Technique

• PCR Based and Microarray Based
• Assay Based Technique
• Massively Parallel Sequencing
• Other

By Application

• Blood Transfusions
• Organ Transplants
• Diagnostic Testing

By End-use

• Hospitals & Clinics
• Diagnostic Laboratories
• Blood Banks
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)